Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases
Open Access
- 6 August 2025
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 24 (11) , 103900
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 132 references indexed in Scilit:
- Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational studyRheumatology International, 2024
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesArthritis & Rheumatology, 2024
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesArthritis Care & Research, 2024
- Pirfenidone use in fibrotic diseases: What do we know so far?Immunity, Inflammation and Disease, 2024
- Interstitial Lung DiseaseJAMA, 2024
- Identification, Monitoring, and Management of Rheumatoid Arthritis–Associated Interstitial Lung DiseaseArthritis & Rheumatology, 2023
- “Management of myositis associated interstitial lung disease”Rheumatology International, 2023
- A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium‐Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic DiseasesClinical Pharmacology in Drug Development, 2021
- Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trialRheumatology International, 2020
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled TrialArthritis & Rheumatology, 2019